INSIDER
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

Robinhood Chain…
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodology
Alerts on Telegram

Congress trades and big insider sales, sent the day they're filed. Free.

Open in Telegram
OverviewFollow the MoneyDaily BriefLiveCongressDirectoryCorporate InsidersPlanned Sales & StakesGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyTelegram alerts
03 · Corporate insiders

Form 4 filings

Officers, directors and 10% owners must report trades within two business days on SEC Form 4. INSIDER parses each filing's XML from EDGAR. By default only discretionary open-market purchases and sales are shown; grants, option exercises and tax withholding are one click away.

Form 4 transactions

Cluster activity · 60d

Most active filers

Companies with the most Form 4 filings
Data sources
SEC Form 45h ago
House PTR5h ago
SEC 13F5h ago
Robinhood Chain5h ago

Most active filers · 30d

  1. 01Kurtz George0B / 215S215 trades$52.62M
  2. 02FWFogarty Patrick W0B / 150S150 trades$600K
  3. 03SPSaba Capital Management, L.P.65B / 19S · 11 late84 trades$21.64M
  4. 04ATAdair Kathleen Theresa52B / 0S · 52 late52 trades$18K
  5. 05AJAllaire Jeremy0B / 50S50 trades$4.26M
  6. 06Wilhelmsen Arne Alexander0B / 47S47 trades$241.96M
  7. 07SJSheena Jonathan0B / 45S45 trades$3.01M
  8. 08SISarowitz Steven I2B / 34S36 trades$22.46M
  9. 09SLSpeiser Michael L0B / 35S35 trades$14.00M
  10. 10RARothblatt Martine A0B / 33S33 trades$5.50M

Cluster activity · 60d

  1. BUYTSMTAIWAN SEMICONDUCTOR MANUFACTURING CO LTDNov 5 – Nov 1732 insiders$917K
  2. SELLDRDDRDGOLD LTDOct 27 – Oct 2710 insiders$1.23M
  3. BUYMTDRMatador Resources CoNov 5 – Nov 109 insiders$765K
  4. SELLMSIMotorola Solutions, Inc.Nov 6 – Nov 168 insiders$42.58M
  5. SELLFFIVF5, INC.Nov 3 – Nov 58 insiders$8.37M
  6. SELLIBEXIBEX LtdNov 9 – Nov 167 insiders$3.36M
  7. SELLMGNIMAGNITE, INC.Nov 5 – Nov 127 insiders$2.27M
  8. SELLSYMSymbotic Inc.Oct 26 – Nov 27 insiders$1.98M

Form 4 transactions

72,500 records
Side
allbuysell
Score
any≥ 30≥ 50≥ 70
Sort
Newest disclosedNewest executedInsider ScoreValue
Include
grants & admin
ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
869 sh
Jan 12, 2026Jan 14, 2026
Page 1481 of 1813
← PrevNext →
traded Jan 12, 2026
+2d
SEC Form 4

Evidence

21
Saba Capital Management, L.P.10% Owner
GFNEW GERMANY FUND INC
Open-market sale
SELL$24K
2,000 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
SB
Starr Daniel BrianDirector
LKFNLAKELAND FINANCIAL CORP
Grant or award
A$18K
309 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$53K
637 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
BJ
Bevirt JoeBenDirector, CEO and Chief Architect, 10% Owner
JOBYJoby Aviation, Inc.
Option exercise
M—
4,371 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$75K
868 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$84K
986 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
OM
Oelschlager Kristen MChief Operating Officer
CSTLCASTLE BIOSCIENCES INC
Grant or award
A—
9,207 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$167K
2,105 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
SW
Simi Bonny WPresident of Operations
JOBYJoby Aviation, Inc.
Option exercise
M—
3,303 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
CS
Chernylo SofiaCAO
NTSTNETSTREIT Corp.
Option exercise
M—
6,033 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
SB
Starr Daniel BrianDirector
LKFNLAKELAND FINANCIAL CORP
Grant or award
A—
650 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

21
SS
Subotovsky SantiagoDirector
ZMZoom Communications, Inc.
Derivative conversion
C—
1.34M sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
MB
McBee BranninChief Development Officer
CRWVCoreWeave, Inc.
Open-market sale · 10b5-1 plan
SELL$65K
776 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
BR
Brumana RodrigoChief Financial Officer
JOBYJoby Aviation, Inc.
Option exercise
M—
1,221 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

21
CS
Chernylo SofiaCAO
NTSTNETSTREIT Corp.
Tax withholding
F$48K
2,694 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,242
14 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
42 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
TP
Tuffin PaulaGeneral Counsel and CCO
BETRBetter Home & Finance Holding Co
Open-market sale · 10b5-1 plan
SELL$297K
7,698 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
PD
Papadopoulos DidierPresident of Aircraft OEM
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$20K
1,367 sh
Jan 13, 2026Jan 14, 2026
traded Jan 13, 2026
+1dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$44K
123 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$745
2 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
92 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$35K
98 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$31K
85 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$14K
39 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$18K
50 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
40 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$34K
96 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,137
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$15K
41 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
DW
Duffy Sean WEVP & Chief Claims Officer
SKWDSkyward Specialty Insurance Group, Inc.
Tax withholding
F$105K
2,276 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
NS
Nagendran SukumarDirector, President and Head of R&D
TSHATaysha Gene Therapies, Inc.
Open-market sale · 10b5-1 plan
SELL$942K
200.0K sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$5,667
15 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$26K
73 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$7,047
19 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

20
FJ
Fitzgerald Kevin JosephCSO & EVP, Head of Research
ALNYALNYLAM PHARMACEUTICALS, INC.
Open-market sale · 10b5-1 plan
SELL$17K
47 sh
Jan 12, 2026Jan 14, 2026
traded Jan 12, 2026
+2dSEC Form 4

Evidence

19
GK
Goodrich KatherineDirector
TARSTarsus Pharmaceuticals, Inc.
Option exercise
M—
2,233 sh
Dec 15, 2025Jan 14, 2026
traded Dec 15, 2025
+30dSEC Form 4

Evidence

19
BG
Bowles GregoryChief Policy Officer
JOBYJoby Aviation, Inc.
Open-market sale · 10b5-1 plan
SELL$79K
5,383 sh
Jan 14, 2026Jan 14, 2026
traded Jan 14, 2026
+0dSEC Form 4

Evidence